Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer

PHASE4RecruitingINTERVENTIONAL
Enrollment

934

Participants

Timeline

Start Date

March 25, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

albumin-bound paclitaxel

Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle

Trial Locations (1)

300000

RECRUITING

Rui Liu, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT05035147 - Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer | Biotech Hunter | Biotech Hunter